CN109475622A - 使用il-33抑制剂抑制过敏反应 - Google Patents

使用il-33抑制剂抑制过敏反应 Download PDF

Info

Publication number
CN109475622A
CN109475622A CN201780014394.8A CN201780014394A CN109475622A CN 109475622 A CN109475622 A CN 109475622A CN 201780014394 A CN201780014394 A CN 201780014394A CN 109475622 A CN109475622 A CN 109475622A
Authority
CN
China
Prior art keywords
ser
thr
val
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780014394.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·隆代伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaptysbio Inc
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of CN109475622A publication Critical patent/CN109475622A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780014394.8A 2016-01-14 2017-01-17 使用il-33抑制剂抑制过敏反应 Pending CN109475622A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278671P 2016-01-14 2016-01-14
US62/278,671 2016-01-14
PCT/US2017/013818 WO2017124110A1 (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Publications (1)

Publication Number Publication Date
CN109475622A true CN109475622A (zh) 2019-03-15

Family

ID=59311527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780014394.8A Pending CN109475622A (zh) 2016-01-14 2017-01-17 使用il-33抑制剂抑制过敏反应

Country Status (12)

Country Link
US (1) US20190016795A1 (https=)
EP (1) EP3402521A4 (https=)
JP (1) JP2019508382A (https=)
KR (1) KR20180101533A (https=)
CN (1) CN109475622A (https=)
AU (1) AU2017208099A1 (https=)
BR (1) BR112018014247A2 (https=)
CA (1) CA3011547A1 (https=)
EA (1) EA201891628A1 (https=)
MX (1) MX2018008732A (https=)
SG (2) SG11201805900YA (https=)
WO (1) WO2017124110A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP2019516362A (ja) 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
GB201712952D0 (en) * 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
EP3694877A1 (en) * 2017-10-09 2020-08-19 AnaptysBio, Inc. Anti-il-33 therapy for atopic dermatitis
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
US20230099101A1 (en) * 2020-03-06 2023-03-30 The Regents Of The University Of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260705A1 (en) * 2007-04-26 2010-10-14 Martin Seamus J Products for altering il-33 activity and methods thereof
US20120207752A1 (en) * 2006-07-20 2012-08-16 Schering Corporation Methods for modulating il-33 activity
US20130287777A1 (en) * 2012-04-30 2013-10-31 Janssen Biotech, Inc. ST2L Antagonists and Methods of Use
WO2014164959A2 (en) * 2013-03-13 2014-10-09 Regeneron Pharmaceuticals, Inc. Anti-il-33 antibodies and uses thereof
CN104334582A (zh) * 2012-05-18 2015-02-04 安进公司 St2抗原结合蛋白
WO2015099175A1 (ja) * 2013-12-26 2015-07-02 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３中和モノクローナル抗体
WO2015106080A2 (en) * 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
CN105007929A (zh) * 2013-03-15 2015-10-28 瑞泽恩制药公司 Il-33拮抗剂和其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101567758B1 (ko) * 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120207752A1 (en) * 2006-07-20 2012-08-16 Schering Corporation Methods for modulating il-33 activity
US20100260705A1 (en) * 2007-04-26 2010-10-14 Martin Seamus J Products for altering il-33 activity and methods thereof
US20130287777A1 (en) * 2012-04-30 2013-10-31 Janssen Biotech, Inc. ST2L Antagonists and Methods of Use
CN104334582A (zh) * 2012-05-18 2015-02-04 安进公司 St2抗原结合蛋白
WO2014164959A2 (en) * 2013-03-13 2014-10-09 Regeneron Pharmaceuticals, Inc. Anti-il-33 antibodies and uses thereof
CN105051063A (zh) * 2013-03-13 2015-11-11 瑞泽恩制药公司 抗-il-33抗体及其用途
CN105007929A (zh) * 2013-03-15 2015-10-28 瑞泽恩制药公司 Il-33拮抗剂和其用途
WO2015099175A1 (ja) * 2013-12-26 2015-07-02 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３中和モノクローナル抗体
WO2015106080A2 (en) * 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHU等: "IL-33,but not thymic stromal lymphopoietin or IL-25,is central to mite and peanut allergic sensitization.", 《J ALLERGY CLIN IMMUNO》 *
LIU X等: "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma.", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
孟欣等: "IL-33/ST2信号转导通路与过敏性鼻炎的研究进展", 《中华中医药杂志》 *

Also Published As

Publication number Publication date
AU2017208099A1 (en) 2018-08-09
EP3402521A4 (en) 2019-11-20
KR20180101533A (ko) 2018-09-12
JP2019508382A (ja) 2019-03-28
CA3011547A1 (en) 2017-07-20
WO2017124110A1 (en) 2017-07-20
US20190016795A1 (en) 2019-01-17
MX2018008732A (es) 2018-12-06
BR112018014247A2 (pt) 2018-12-18
EA201891628A1 (ru) 2018-12-28
SG10202006699XA (en) 2020-08-28
EP3402521A1 (en) 2018-11-21
SG11201805900YA (en) 2018-08-30

Similar Documents

Publication Publication Date Title
CN109475622A (zh) 使用il-33抑制剂抑制过敏反应
US20240294631A1 (en) Antibodies directed against interleukin-33 (il-33)
US10836824B2 (en) Antibodies directed against lymphocyte activation gene 3 (LAG-3)
CN111902428B (zh) 一种双特异性抗体及其用途
WO2021063336A1 (zh) 靶向cldn18.2的抗体及其制备方法和应用
JP6866345B2 (ja) Ｉｌ−２３ａ及びｂ細胞活性化因子（ｂａｆｆ）を標的とする化合物及びその使用
BR112020012011A2 (pt) moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica.
EP3770176A1 (en) Antibodies directed against programmed death-1 (pd-1)
TR201902033T4 (tr) Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
TW201010725A (en) Anti-IL-12/IL-23 antibodies
JP7697106B2 (ja) Ｐｄ－１アゴニストおよびそれを使用する方法
CN115461371B (zh) 靶向ox40的抗体及其制备方法和应用
HK1204328A1 (en) Human growth hormone receptor antagonist antibodies and methods of use thereof
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
WO2019183639A1 (en) Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
WO2020098785A1 (zh) 人源化抗人pd-l1单克隆抗体及其制备方法和用途
HK40004844A (en) Inhibition of allergic reaction using an il-33 inhibitor
RU2829846C2 (ru) Антитела, направленные против интерлейкина-33 (il-33)
CA2936366C (en) Antibodies directed against interleukin-33 (il-33)
CN114555120A (zh) 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
BR112015026823B1 (pt) Anticorpo da proteína de morte-1 programada (pd-1) isolada, composição compreendendo o mesmo e uso da composição
HK1242616B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004844

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315